Baricitinib 4mg and 2mg Once-Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials

被引：0
|
作者：
Pope, Janet [1 ]
Lee, Yvonne [2 ]
Curtis, Jeffrey [3 ]
Mo, Daojun [4 ]
Rooney, Terence [4 ]
Xie, Li [4 ]
Dickson, Christina [4 ]
Schlichting, Douglas [4 ]
Quebe, Amanda [4 ]
Cardoso, Anabela [4 ]
Simon, Lee [5 ]
Taylor, Peter [6 ]
机构：
[1] Western Univ, Div Rheumatol, Dept Med, London, ON, Canada
[2] Brigham & Womens Hosp, Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] SDG LLC, Boston, MA USA
[6] Univ Oxford, Oxford, England
来源：
JOURNAL OF RHEUMATOLOGY | 2020年 / 47卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
240
引用
收藏
页码：1129 / 1130
页数：2
相关论文
共 13 条
  • [1] Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials
    Pope, Janet
    Lee, Yvonne
    Curtis, Jeffrey
    Mo, Daojun
    Rooney, Terence
    Xie, Li
    Dickson, Christina
    Schlichting, Douglas
    Quebe, Amanda
    Cardoso, Anabela
    Simon, Lee
    Taylor, Peter
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [2] Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily
    Fleischmann, Roy
    Genovese, Mark C.
    Cardoso, Anabela
    Sun, Luna
    Chen, Yun-Fei
    Walls, Chad D.
    Schlichting, Douglas E.
    Takeuchi, Tsutomu
    Dougados, Maxime
    Smolen, Josef S.
    Curtis, Jeffrey R.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [3] Risk of Adverse Drug Events Observed with Baricitinib 2mg Versus Baricitinib 4mg Once Daily for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Huang, Feng
    Luo, Zu-chun
    BIODRUGS, 2018, 32 (05) : 415 - 423
  • [4] Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib
    Pope, Janet E.
    Lee, Yvonne C.
    Curtis, Jeffrey R.
    Mo, Daojun
    Xie, Li
    Dickson, Christina L.
    Schlichting, Douglas E.
    Cardoso, Anabela
    Simon, Lee S.
    Taylor, Peter C.
    ACR OPEN RHEUMATOLOGY, 2022, 4 (03) : 254 - 258
  • [5] Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study
    Alvin F. Wells
    Bochao Jia
    Li Xie
    Guillermo J. Valenzuela
    Edward C. Keystone
    Zhanguo Li
    Amanda K. Quebe
    Kirstin Griffing
    Susan Otawa
    Boulos Haraoui
    Rheumatology and Therapy, 2021, 8 : 987 - 1001
  • [6] Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study
    Wells, Alvin F.
    Jia, Bochao
    Xie, Li
    Valenzuela, Guillermo J.
    Keystone, Edward C.
    Li, Zhanguo
    Quebe, Amanda K.
    Griffing, Kirstin
    Otawa, Susan
    Haraoui, Boulos
    RHEUMATOLOGY AND THERAPY, 2021, 8 (02) : 987 - 1001
  • [7] PREDICTORS OF DURABLE CLINICAL RESPONSE TO TOFACITINIB 11 MG ONCE DAILY WITH OR WITHOUT METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: POST HOC ANALYSIS OF DATA FROM A PHASE 3B/4 METHOTREXATE WITHDRAWAL STUDY
    Yamaoka, K.
    Cohen, S. B.
    Sugiyama, N.
    Shi, H.
    Rivas, J. L.
    Diehl, A.
    Smolen, J. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 563 - 564
  • [8] Predictors of Durable Clinical Response to Tofacitinib 11 Mg Once Daily with or Without Methotrexate in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Data from a Phase 3b/4 Methotrexate Withdrawal Study
    Yamaoka, Kunihiro
    Cohen, Stanley B.
    Sugiyama, Naonobu
    Shi, Harry
    Rivas, Jose L.
    Diehl, Annette
    Smolen, Josef
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [9] EARLY PATIENT-REPORTED OUTCOMES AND CLINICAL OUTCOMES WITH ABT-494 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO ARE INADEQUATE RESPONDERS TO METHOTREXATE OR TUMOR NECROSIS FACTOR INHIBITORS: POST-HOC ANALYSIS OF PHASE 2 RANDOMIZED CONTROLLED TRIALS
    Strand, V.
    Tundia, N.
    Song, I. H.
    Meerwein, S.
    Lin, J.
    Chen, N.
    Friedman, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 855 - 855
  • [10] METHOTREXATE WITHDRAWAL IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVE LOW DISEASE ACTIVITY WITH TOFACITINIB MODIFIED-RELEASE 11 MG ONCE DAILY plus METHOTREXATE: A RANDOMISED NON-INFERIORITY PHASE 3B/4 STUDY
    Cohen, Stanley B.
    Pope, Janet
    Haraoui, Boulos
    Irazoque-Palazuelos, Fedra
    Korkosz, Mariusz
    Diehl, Annette
    Luis Rivas, Jose
    Lukic, Tatjana
    Liu, Shixue
    Stockert, Lori
    Iikuni, Noriko
    Keystone, Edward
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 260 - 261
12